- Company postpones Extraordinary General Assembly from May 5, 2020 to June 8, 2020
Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the decision to host its 2020 Ordinary General Meeting remotely on May 5, 2020 and to postpone its Extraordinary General Meeting to June 8, 2020 from May 5, 2020.
Materials for both the Ordinary and Extraordinary Shareholders’ Meetings can be found on the Investors section of the Company’s website under “Shareholder Meetings”.
Ordinary Shareholders’ Meeting of May 5, 2020
In view of the current exceptional circumstances linked to the COVID-19 pandemic and in accordance with Belgian Royal Decree No. 4 of April 9, 2020, the Board of Directors of Celyad have decided to prohibit the physical presence of shareholders, and instead will webcast the Ordinary General Meeting of May 5, 2020 remotely, via an electronic means of communication.
The detailed practical arrangements for the broadcasting of this Ordinary General Meeting will be published on Celyad’s website.
Voting instructions can only be submitted by proxy to the proxyholder designated by the Board of Directors of Celyad. With respect to the right to ask questions, shareholders are allowed to submit their questions only in writing prior to the Ordinary General Meeting.
The other formalities for admission to and participation in the meeting (conditions of admission, right to ask questions and consultation of the available documents) remain unchanged from the information provided in the notice of meeting published on April 3, 2020.
Extraordinary Shareholders’ Meeting of May 5, 2020
In addition, the Board of Directors of Celyad have also decided to postpone the Extraordinary General Meeting initially scheduled for May 5, 2020 until June 8, 2020 at 3:00 pm CEST. The agenda of this meeting will remain the same, including:
- Acknowledgement of the special report of the Board of Directors drawn up in accordance with article 7:199 of the Companies and Associations Code
- Renewal of authorized capital
- Change the Company’s name
This postponement decision was adopted in view of the exceptional circumstances related to the COVID-19 pandemic and, specifically, the difficulties encountered by our shareholders of the American depositary receipts in expressing their vote if the date of May 5, 2020 had been maintained. As a reminder, the meeting had been convened with a reduced notice period in application of article 7:128 §1 of the Code of Companies and Associations.
Information on the modalities and other arrangements made for the holding of this Extraordinary General Meeting will be communicated at a future date.